A Phase 1 Single-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs TBX-3400 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Taiga Biotechnologies
- 17 Sep 2018 Planned initiation date changed from 1 May 2018 to 1 Nov 2018.
- 31 Aug 2018 Biomarkers information updated
- 23 Apr 2018 Planned initiation date changed from 1 Jan 2018 to 1 May 2018.